It's a big blow for the industry.

We have to do regular checks of our staff every six months and we have found no lung or any other health problem for 10 or 15 years.

We think this is a good move for Johnson and Johnson. It boosts their pharmaceutical (sales) growth also brings them expertise in research and development of drug delivery.

These are dedicated doctors, who take care of very sick patients. It's a doctor's duty to care. Care in the field doesn't change.

Physicians themselves haven't lost anything. As long as revenue is there, they're getting paid.

The company gave me confidence that they have next-generation products for markets that they currently participate in. Additionally, for the large markets where they are not players, the company is developing compounds.